BMC Cancer

Table 3 Prognostic value of IGF1R intensity in ER-negative and ER-positive patients in Cohort I (a) and II (b), respectively

From: Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer

a)
Cohort I		DDFS univariable				DDFS multivariable^a
		N	HR	95% CI	p-value	N	HR	95% CI	p-value
Cytoplasm	All patients	264	0.70	0.52-0.94	0.016	220	0.80	0.57-1.1	0.18
	ER+	174	1.2	0.76-2.0	0.40	152	1.21	0.72-2.0	0.46
	ER-	80	0.62	0.40-0.96	0.033	68	0.49	0.29-0.82	0.007
Membrane	All patients	264	0.58	0.39-0.86	0.007	220	0.71	0.46-1.1	0.13
	ER+	174	0.89	0.54-1.5	0.63	152	0.91	0.54-1.5	0.72
	ER-	80	0.44	0.20-0.97	0.041	68	0.32	0.13-0.79	0.014
b)
Cohort II		DDFS univariable				DDFS multivariable ^b
		N	HR	95% CI	p-value	N	HR	95% CI	p-value
Cytoplasm	All patients	206	0.87	0.52-1.5	0.61	179	1.0	0.59-1.8	0.91
	ER+	139	1.1	0.48-2.5	0.83	122	1.2	0.53-2.9	0.62
	ER-	67	0.81	0.42-1.56	0.53	57	0.71	0.32-1.6	0.39
Membrane	All patients	206	0.87	0.53-1.4	0.57	179	1.03	0.57-1.9	0.92
	ER+	139	1.3	0.64-2.5	0.51	122	1.2	0.59-2.5	0.60
	ER-	67	0.72	0.34-1.5	0.37	57	0.84	0.31-2.3	0.74

^aMultivariable Cox-regression for IGF1R intensity adjusted for node positivity, tumor size, HER2, Ki67, menopausal status and, among all patients, ER status.
^bMultivariable Cox-regression for IGF1R intensity adjusted for age, tumor size, HER2, Ki67 and, among all patients, ER status.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com